Select Publications

Gradishar W et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2007;Abstract 1032.

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Hart LL et al. A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): Preliminary results. Proc ASCO 2008;Abstract 575.

Vukelja S et al. A phase II study of trastuzumab-DM1, a first-in-class HER2 antibodydrug conjugate, in patients with HER2+ metastatic breast cancer. Presentation. San Antonio Breast Cancer Symposium 2008;Abstract 33.

Yardley DA et al. Preliminary safety results: Addition of bevacizumab to 3 docetaxel
regimens as adjuvant therapy for early stage breast cancer. Poster. San Antonio Breast Cancer Symposium 2008a;Abstract 4107.

Yardley DA et al. Preliminary progression free survival and SPARC tumor correlatives from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab paclitaxel. Poster. San Antonio Breast Cancer Symposium 2008b;Abstract 5116.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Harold J Burstein, MD, PhD
- Select publications

Jack Cuzick, PhD
- Select publications

Howard A Burris III, MD
- Select publications

Mark D Pegram, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office